<DOC>
	<DOCNO>NCT01185496</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness G4 System wear 7-days child adolescent subject ( 6 &lt; 18 years-old ) type 1 diabetes mellitus .</brief_summary>
	<brief_title>Effectiveness Safety Study DexCom™ G4 Continuous Glucose Monitoring System Children Adolescents With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Device performance primarily evaluate term proportion G4 System value within ±20 % study meter reference value glucose level &gt; 80 mg/dL ±20 mg/dL meter glucose level &lt; 80 mg/dL . This proportion compare proportion point observe DexCom clinical study use apply FDA approval G4 System ( PTL 900360 ) adult . Safety data G4 System also collect safety characterize incidence Adverse Device Effects , Serious Adverse Device Events , Unanticipated Adverse Device Effects experience study participant .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Age 6 &lt; 18 yearsold ; 2 . Have diagnose type 1 diabetes mellitus multiple daily injection ( MDI ) Continuous Subcutaneous Insulin Infusion ( CSII ) insulin therapy ; 3 . Willing inject insulin wear insulin pump insertion set within 3 inch Sensor site Sensor wear ; 4 . Willing use blood glucose meter provide selfmonitoring blood glucose ( SMBG ) Sensor wear , willing adhere protocolspecified fingerstick schedule home use ; 5 . Willing participate three consecutive 7day Sensor wear period ; 6 . Willing take minimum 7 fingersticks per day home use ( 2 calibration purpose , 5 comparative purpose ) ; 7 . Willing refrain use acetaminophen Sensor insertion period least 24hours prior Sensor insertion ; 8 . Willing schedule magnetic resonance ( MRI ) scan , compute tomography ( CT ) scan , xray , duration study ; 9 . Both subject guardian able speak , read , write English . 1 . Have extensive skin changes/diseases preclude wear Sensor normal skin ( e.g . extensive psoriasis , recent burn severe sunburn , extensive eczema , extensive scarring , extensive tattoo , dermatitis herpetiformis ) propose wear site ; 2 . Subjects know allergy medicalgrade adhesive ; 3 . For participant childbearing potential : pregnant demonstrate positive pregnancy test within 72 hour insertion ( sexually active participant childbearing potential must use birth control study ) ; 4 . Have hematocrit less 30 % , great 55 % ; 5 . Current participation another investigational study protocol ( subject recently complete participation another drug study , subject must complete study least 30 day prior enrol study ) ; 6 . Have condition , opinion Investigator , would interfere participation trial pose excessive risk study staff ( e.g. , known history hepatitis B C ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>diabetes mellitus</keyword>
</DOC>